SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 647.19+0.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotechwantabe who wrote (3135)11/5/2020 8:16:52 AM
From: Biotechwantabe  Read Replies (1) of 3557
 
On partnership and row sales:

Eylea
US 1318m +11%
Row 780m +7(bayer is a lazy partner)

Dupi
Us 851
Row 221 (sanofi is not performing)

Cov2
Will Roche perform?

It’s about time for regeneron to accept responsibility for row sales vs leaving it to partners. Either that or sellout. Another example of not investing enough in themselves.

I really shouldn’t complain as I’m making a fortune on their stock. But I think they need to change their approach.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News